Enanta Pharmaceuticals (ENTA) Cash from Investing Activities Growth (3y) (2015 - 2026)
Enanta Pharmaceuticals (ENTA) Cash from Investing Activities Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - | -36.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.56% |
| Dec 31, 2025 | -50.50% |
| Sep 30, 2025 | -56.67% |
| Jun 30, 2025 | -53.73% |
| Mar 31, 2025 | 50.05% |
| Dec 31, 2024 | 14.83% |
| Sep 30, 2024 | -35.98% |
| Jun 30, 2024 | 47.44% |
| Mar 31, 2024 | 32.05% |
| Dec 31, 2023 | 9.07% |
| Sep 30, 2023 | 67.83% |
| Jun 30, 2023 | -95.24% |
| Mar 31, 2023 | 19.00% |
| Dec 31, 2022 | 42.64% |
| Sep 30, 2022 | 36.45% |
| Jun 30, 2022 | 45.69% |
| Mar 31, 2022 | -205.52% |
| Dec 31, 2021 | 61.01% |
| Sep 30, 2021 | 123.36% |
| Jun 30, 2021 | -11.58% |